The Swedish oncology drug developer Immunicum AB has appointed a new management team following its merger with DCprime of the Netherlands in December 2020. Leading the team as chief executive is Erik Manting, formerly CEO of DCprime and before that, head of corporate finance at Kempen & Co.
Alex Karlsson-Parra, chief scientific officer of Immunicum, continues in this role at the combined company and Jeroen Rovers has been named chief medical officer. Dr Rovers was previously managing director of DCprime and before that CMO of the Dutch company.
Immunicum announced the appointments on 16 March 2021.
Copyright 2021 Evernow Publishing Ltd